In this paper we report the analysis of seven benzopyridoindole and benzopyridoquinoxaline drugs binding to different duplex DNA and triple helical DNA, using an approach combining electrospray ionization mass spectrometry (ESI-MS), tandem mass spectrometry (MS/MS), and molecular modeling. The ligands were ranked according to the collision energy (CE 50 ) necessary to dissociate 
INTRODUCTION MATERIALS AND METHODS

Materials
The self-complementary duplexes Dk33 (dCGTAAATTTACG) 2 , Dk66
(dCGCGAATTCGCG) 2 , and Dk100 (dCGCGGGCCCGCG) 2 were prepared in 100 mM aqueous NH 4 OAc. All stock solutions were diluted to 50 µM at neutral pH. The triple helical DNA was prepared in 150 mM NH 4 OAc acidified with acetic acid (pH = 5.5), as previously described [47] . The triplex was formed from single strands dCCTTTTCTCTTTCC (T1), dGGAAAGAGAAAAGG (T2), which constitute a Watson-Crick duplex (T1•T2), and the strand dCCTTTCTCTTTTCC (T3) which is the antigene strand. Sequence T3 is the reverse of sequence T1. The oligonucleotides were purchased from Eurogentec (Seraing, Belgium) and used without further purification.
The synthesis of the benzo[e]pyridoindole 1 (CA: 125974-68-7) and the benzo[f]pyridoindole 2 (CA: 170890-29-6) was described in 1990 [33] , the synthesis of the benzo[f]pyridoquinoxalines 3 (CA:
165548-08-3), benzo[h]pyridoquinoxalines 4 (CA: 165548-10-7) and 5 (CA: 165548-11-8) and of the pyridoquinoxaline 7 (CA: 165548-02-7) was described in 1995 [39] , and the synthesis of the benzo[f]quinoquinoxaline 6 (CA: 373595-26-7) was reported in 1998 [43] . The drug stock solutions were 100 or 200 µM in bi-distillated water.
For ESI-MS, drug-duplex mixtures of 10 µM DNA and 15 µM drug were prepared in 150 mM NH 4 OAc and 15% methanol. The small proportion of methanol used (15%) does not disturb the particular DNA structures used in our assay as verified by CD (data not shown) and the high ionic strength used prevents the AT-rich duplex and the triplex from unfolding. The concentrations of the DNA stock solutions were checked no more than 3 days before the ESI-MS experiments by UV absorbance measurements.
Mass Spectrometry
ESI-MS experiments were performed on a LCQ instrument (Finnigan LCQ ion trap instrument (ThermoFinnigan, SanJose, CA) equipped with its standard heated capillary electrospray source or a Q-TOF Ultima Global (Micromass, now Waters, Manchester, UK) with its standard ESI source. On the LCQ, the needle voltage was set to -3.9 kV. The capillary was heated to 180 °C and the applied potential was -10 V. The skimmer was at ground potential and the tube lens offset was maintained at 40V. On the Q-TOF, in negative ion mode the capillary voltage was set to −2. 
where C 0 is the starting DNA concentration (expressed in duplex or triplex concentration), I( DNA) is the relative intensity of the free DNA, and I (n:1) are relative intensities of the complexes (n drug molecules bound to one DNA structure). The concentrations of bound ligand were found independent on the instrument used.
MS/MS experiments were all performed on the Q-TOF Ultima Global. This choice was done for two reasons. First, the mass range of the LCQ is limited to 2000 m/z and some triple helix fragments are observed m/z > 2000. Second, thanks to the higher-energy collision regime of the Q-TOF, direct noncovalent bond breaking is favored compared to rearrangement reactions giving neutral base losses [48] . The parent ion of interest was selected in the first quadrupole, and the hexapole collision voltage was varied. The argon pressure in the collision hexapole (3.0 × 10 −5 mbar ± 5%) and the source pressure (2.70 mbar) were carefully kept constant. Source block and desolvation temperatures were set to 70
• C and 100
• C, respectively.
Molecular modeling
Hyperchem 7.5 software (Hypercube, Inc.) has been used with AMBER99 force field. The starting duplex d(CGCGAATTCGCG) 2 was the solution structure deposited in the Protein Data Bank with code 1GIP [49] . As these ligands are known to bind DNA by intercalation [34, 41, 42] , three different intercalation sites on the duplex d(CGCGAATTCGCG) 2 have been independently generated as follows. First, an increase of the space between two base pair by 3.4 Å was performed. Second, the twist angle of the helix (including one of the two base pair involved in the intercalation site) was decrease by 10 degree to compensate the change in the distance between the sugar-phosphate backbones. These parameters were chosen based on the structures of complexes between duplex DNA and intercalators found in PDB entries 2DES [50] and 1D10 [51] . Finally, local geometry optimization including the two base pairs and the backbone involved the intercalation site and the sugar-phosphate surrounding the site was performed to relax the system. Local geometry optimization was performed to relax the backbone surrounding the intercalation site. The intercalation sites were CG*CG, CG*AT and AT*AT. The global effect of the intercalation site on the duplex was the increase of the dimension of the grooves due to the decrease of the twisting angle of the two base pairs of the intercalating site. Each drug was manually docked in the intercalation site in different orientations as described in the text below, and energy minimized in the force field generated by the duplex until an energy gradient of 0.05 kcal/(mol.Å) was reached (Polak-Riebiere conjugate gradient algorithm). The maximum gradient of the generated ligand-DNA was never higher than 0.3 kcal/(mol.Å) which is satisfactory (the DNA without drug has at a gradient of 0.2 kcal/(mol.Å) and indicated that no steric clash/problem is encountered.
The same methodology as for the duplex was used to generate the intercalation sites and calculate the interaction energies between the drugs and the triplex. The starting triplex model was generated using a smaller triple helical DNA (7 triplets) based on the NMR solution structure of a pyrimidine-purinepyrimidine DNA triplex (PDB entry 149D) [52] . Two intercalation sites between the base-triplet were generated: CGC-TAT and TAT-TAT.
The interaction energy was calculated using the following equation (2):
Where E (complex) is the complex energy, E (ligand) is the energy of the ligand with its geometry in the complex, and E (duplex) is the energy of the duplex with its geometry in the complex.
RESULTS AND DISCUSSIONS
ESI-MS determination of ligand selectivity.
The sequence and structural selectivities of the seven compounds were first probed using ESI-MS ( Figure 1 ). Figure 1 
where the benzene ring is linked to the other side on the quinoxaline. Ligand 7, which has the smallest heteroaromatic ring, has the lowest affinity for both DNA structures. Taken together, these observations suggest that the shape of the heteroaromatic ring system of these drugs therefore plays an important role in stacking interactions with the base triplets.
ESI-MS/MS and molecular modeling on the (1:1) duplex-ligand complexes
In the case of duplex-drug complexes, we have previously classified drugs in three categories, based on their dissociation pattern in tandem mass spectrometry experiments [54] . The first group includes drugs for which the complex dissociates mainly via the loss of a neutral drug. For the second group, the complex dissociates mainly via the loss of a negatively charged drug and for the third group via the separation of the strands (noted ss) which share the available charges and some drug molecule could stick on both strands. Here we have performed MS/MS experiments on the 1:1 (Drug-Dk66) complex ( Figure 2 ). All the complexes with each of the seven drugs dissociate mainly via the loss of a neutral drug.
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In the case where the dissociation mechanism is the same for a series of ligands, the CE 50 values are directly related to the activation energy of dissociation. This condition is fulfilled here as (1) the dissociation pathways are identical and (2) the parallel dissociation curves indicate similar activation entropies. Moreover, if the dissociation involves the loss of neutral ligand from the charged duplex, which is the case here, the activation energy is more likely to be proportional to the ligand binding energy [54] .
The dissociation pattern observed for all ligands is the same as for the drugs of the first group like cryptolepine, proflavine, daunomycin and doxorubicin [54] . The percentage of intact complex is calculated using the following equation (4) The competitive dissociation of the duplex into the single strands (ss 3-and ss 2- ) is only observed at collision energies > 18 eV, so this fragmentation channel does not perturb the ordering of CE 50 . The two BPI ligands 1 and 2 leave the duplex at higher energy than the quinoxaline derivatives (3-7).
Among the quinoxaline derivatives, 6 has the largest interaction energy with its binding site on the duplex (since higher collision energy is needed to dissociate the complex as compared to the other BPQ drugs).
We performed molecular modeling to compare the interaction energies of a drug with different binding site sequences on duplex d(CGCGAATTCGCG) 2 and to correlate the calculated interaction energies to the relative CE 50 values obtained by MS/MS. Several groups have examined the molecular recognition and the dynamics of drug-DNA interactions using molecular modeling [55] [56] [57] . As the energetic parameters calculated by molecular modeling are related to the gas phase, the calculation using molecular modeling of the energetic of drug-DNA complexes allows a direct comparison with MS/MS experiments.
The intercalation binding mode of these ligands was demonstrated previously [34, 41, 42] . Here two configurations were studied for each intercalation site: the alkyl chain of the drug can be oriented in two directions (Figure 3(a) ). The central intercalation site is symmetric and only one orientation of the alkyl chain was studied for the CG*CG intercalation site (to prevent the aminoalkyl chain from going outside the duplex). The planar aromatic rings of the drugs were inserted into the duplex, with the alkyl chain laying in the minor groove allowing interaction between the side chain and the groove of the helix [34, 41, 42] . Small molecules generally interact via the DNA minor groove because it is narrower and more electronegative than the major groove, providing more favorable interactions with the ligand [58] . Only a small number of drugs like the bis-intercalator ditercalinium [59] , or drugs that have large bulky groups [60] , bind to duplex DNA through the major groove. It is noteworthy that the interaction energies calculated for the intercalation site CG-CG, AT-AT and CG-AT follow roughly the same ranking order as in the MS/MS experiments. Only the E int obtained for the intercalation site CG-AT with the aminoalkyl tail oriented toward the GC-side ("up")
does not follow the experimental trend. The absence of a significant dependence of interaction energies on the base sequence is in agreement with the absence of sequence selectivity observed for the duplex in full scan ESI-MS: figure 1(b) shows that the amount of bound ligand does not change according with the GC content of the duplex. In the population of complexes selected for MS/MS, the probability of the ligand being in GC-rich sites is therefore supposed to be proportional to the fraction of these sites. It must be pointed out that no drug is observed on the antigene strand, suggesting a stronger interaction with the Watson-Crick duplex part of the triplex. Figure 4 (b) shows the dissociation curves obtained for each drug. The percentage of intact complex is calculated using Equation (5), which is valid for both cases (intensities are replaced by zero when appropriate). For the molecular modeling, two intercalation sites were generated using the same procedure as for duplex: CGC-TAT and TAT-TAT. Four starting intercalation geometries were generated for each site: two with the drug docked with the alkyl chain in the major groove with the aminoalkyl chain going "up" (ie: amino group of the alkyl chain toward the 3' end of the antigen strand) and "down" (aminoalkyl chain toward the 5' end of the antigen strand) and two by intercalating the drug with the alkyl chain in the minor groove, and testing the two orientations of the chain (Figure 5(a) ). A total of eight binding modes were therefore tested for each drug. We checked that the optimized conformations of the triplex with ligand 4 and 6 were stable in vacuo by running lengthy dynamics simulation (total of 5 ns) at the temperature of 300 K (data not shown). Although the helical conformation is slightly distorted (especially the 3' end of the antigene strand), hydrogen bonding in the base triplets involved in the ligand binding site is well conserved, and ligand binding mode remains the same as shown in Figure 5 (c), thereby validating our modelling approach.
ESI-MS/MS and molecular modeling on the (1:1) triplex-ligand complexes
The calculated interaction energies for the different binding sites are summarized in Table 2 with the corresponding experimental voltage to observe 50 % dissociation (CE 50 ) obtained by tandem mass spectrometry. The calculated interaction energies are the most favorable for the TAT-TAT binding site with the aromatic rings of the drugs inserted through the minor groove of the WatsonCrick duplex and the aminoalkyl chain in the minor groove. For that binding site, the interaction energies follow the same ranking as the experimentally determined CE 50 (Table 2 ). which a significantly lowest energy site corresponds to the aminoalkyl chain in the major groove. In previous structure-affinity relationships and molecular modeling for BePI and BgPI derivatives, it was already suggested that the aminoalkyl chain was located in the minor groove of the duplex for BgPIs like 2 and in the major groove together with the antigene strand for BePIs like 1 [34] . Our calculations are also in line with this model and, coming back the MS/MS results, the fact that the breakdown curves of ligands 1 and 2 are not parallel can now be interpreted as an influence of the ligand binding mode on the activation entropy of dissociation. This illustrates that (1) a careful interpretation of the breakdown curves allows guessing that two of the ligands might have different binding modes, and (2) molecular modeling calculations, even at the modest level used here, could allow identifying the correct binding mode.
CONCLUSION
The major conclusions of the present work are as follows. The benzopyridoindoles (1 and 2) have larger interaction energies than the pyridoquinoxalines (3-7) . The nature of the heteroaromatic rings therefore plays a major role in the affinity of the ligand for the target. However, the benzopyridoindoles do not show any selectivity for the triplex compared to the duplex (see Figure 1 ). Molecular modeling indeed shows that BPI drugs interact preferentially with the Watson-Crick duplex and have small interaction with the antigen strand. Among the benzopyridoquinoxalines, the three most selective ligands (4, 5 and 6) all share the same heteroaromatic core, which best stacks on a base triplet (see the triplex. The % of intact complex is calculated using Equation (5) for each collision energy.
